



# Acceptable, hopeful, and useful: development and mixed-method evaluation of an educational tool about reproductive options for people with sickle cell disease or trait

Macy L. Early<sup>1,2</sup> · Rachel J. Strodel<sup>1</sup> · Isabel V. Lake<sup>1</sup> · Jake A. Ruddy<sup>1</sup> · James A. Saba<sup>1,3</sup> · Sajya M. Singh<sup>1</sup> · Sophie Lanzkron<sup>1,2</sup> · Jennifer W. Mack<sup>4</sup> · Emily R. Meier<sup>5</sup> · Mindy S. Christianson<sup>1,6</sup> · Lydia H. Pecker<sup>1,2</sup>

Received: 20 September 2021 / Accepted: 12 November 2021 / Published online: 22 November 2021  
© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2021

## Abstract

**Purpose** People with sickle cell disease (SCD) or trait have many reproductive options, some of which decrease the chance of passing SCD to children, including in vitro fertilization with preimplantation genetic testing (IVF + PGT). Few are aware of these options, and educational materials are needed. This study aimed to develop an accessible, non-directive patient education material about reproductive options for those with SCD or trait via a process that incorporated stakeholders from the SCD community.

**Methods** Multidisciplinary stakeholders guided development and revision of a novel pamphlet. Researchers applied health literacy scales to measure pamphlet understandability. We interviewed nine patients with SCD and six multidisciplinary clinicians to evaluate the pamphlet. Interviews were recorded, transcribed, and coded by a five-member team who developed a codebook and proposed themes that were revised by all research team members. Feedback was incorporated into a revised pamphlet.

**Results** A two-page pamphlet describing reproductive options for people with SCD including IVF + PGT was acceptable to key stakeholders, including people with SCD. Material about this complex topic met health literacy standards, including being written at a 5th grade level. Patients reported feeling hopeful after reviewing the pamphlet, and participants considered the pamphlet useful, clear, and appropriate for distribution in clinics and online.

**Conclusions** Though awareness of reproductive options for those with SCD or trait is low, patients and providers find a novel pamphlet about this topic acceptable and useful. Educational materials about complex topics including IVF + PGT can be written at a level understandable to the average American.

**Keywords** Sickle cell · Patient education · Reproduction · Assisted reproduction · Preimplantation genetic testing

---

Isabel V. Lake, Jake A. Ruddy, James A. Saba and Sajya M. Singh contributed equally to the work.

✉ Macy L. Early  
mearly4@jhmi.edu

<sup>1</sup> Johns Hopkins University School of Medicine, Baltimore, MD, USA

<sup>2</sup> Division of Hematology, Department of Medicine, Baltimore, MD, USA

<sup>3</sup> Medical Scientist Training Program, Baltimore, MD, USA

## Introduction

Individuals with sickle cell disease (SCD) and sickle cell trait (SCT) are at risk of passing SCD, a morbid autosomal recessive disease, to their offspring [1]. Reproductive options for these individuals include genetic carrier

<sup>4</sup> Dana-Farber Cancer Institute/Boston Children's Hospital, Boston, MA, USA

<sup>5</sup> Indiana Hemophilia and Thrombosis Center, Indianapolis, IN, USA

<sup>6</sup> Division of Reproductive Endocrinology and Infertility, Department of Gynecology and Obstetrics, Baltimore, MD, USA

screening with partner selection, spontaneous pregnancy with or without prenatal testing, in vitro fertilization with preimplantation genetic testing (IVF + PGT), IVF with use of unaffected donor egg or sperm, adoption, or forgoing having children. IVF + PGT is an over 20-year-old technology that reduces the chance of having a child with SCD by over 98% [2]. Recent studies identify that individuals with SCD and their parents have limited awareness, but high levels of interest in IVF + PGT [3–6]. Individuals with SCD or SCT use IVF + PGT less often than people with other conditions of similar prevalence, including cystic fibrosis [7].

There are individual-, provider-, and system-level barriers to providing comprehensive reproductive counseling that includes IVF + PGT for people with the chance of having a child with SCD [8]. Many individuals do not know their hemoglobinopathy trait status despite universal newborn screening in the USA [9], and unplanned pregnancy is common [10]. While primary care providers, hematologists, and obstetricians-gynecologists commonly encounter people who could pass SCD to their children, there is no established “work flow” to ensure those individuals receive proper testing and counseling. Furthermore, providers report discomfort explaining IVF + PGT to patients due to its technological complexity [11]. Providers might also neglect this topic because the high cost of IVF + PGT in the USA limits access for many patients. While some patients might attempt to educate themselves about reproductive options, written materials that describe the process of IVF + PGT are written at a college reading level [12], while the average American adult cannot read a book at the eighth-grade level [13].

Tools to navigate complex reproductive counseling that support non-judgmental, shared decision-making are needed for individuals with SCD and SCT and their providers. Reproductive choices are highly individualized decisions informed by historical and cultural contingencies. In the USA, where couples at risk for SCD are disproportionately Black, reproductive coercion of African American women [14] and advocacy for eugenic approaches to “eradicate SCD” [15, 16] may inform community perspectives and provider behavior. Reproductive choices may feel morally ambiguous and emotional, especially as they relate to preventing a genetic condition. Incorporating opinions of members of the affected community can help ensure judicious presentation of a sensitive topic and understand the needs and perspectives of the target audience.

The purpose of this study was to develop an accessible, non-directive patient education material about reproductive options for those at risk of having a child with SCD using a participatory process with stakeholders from the SCD community. We hypothesized that this pamphlet could be designed to meet national plain language standards [17, 18] and be acceptable and understandable to patients and healthcare providers.

## Methods

The Johns Hopkins Institutional Review Board approved this study. Our three-step approach to pamphlet development, evaluation, and revision is described here (Fig. 1). These methods adhered to the Standards for Reporting Qualitative Research [19] (Supplemental material 1).

### Pamphlet development

We reviewed existing educational materials about reproductive options for genetic conditions [20–22] and assisted reproductive technologies (ART) [12] to select the pamphlet content. We also met with a geneticist, genetic counselor, hematologist, reproductive endocrinologist, and two SCD-focused community health workers, one of whom has SCT and is the mother of a child with SCD, for input on content.

Two collaborators created the text, layout, and graphics using Canva [23]. Toolkits from the Centers for Disease Control and Prevention (CDC), Agency for Healthcare Research and Quality (AHRQ), and Center for Medicare and Medicaid Services [24–26], containing research-supported techniques to enhance patient understanding, guided the pamphlet’s design.

A multidisciplinary SCD research group reviewed the initial draft. This group included hematologists, SCD research staff, trainees, and public health professionals. The pamphlet was revised with this group’s feedback prior to formal evaluation.


### Pamphlet evaluation

#### Health literacy scales

Graders assessed the pamphlet’s adherence to health literacy standards using three tools. The Flesch-Kincaid measures the reading grade level required to understand a text [27]. The Flesch-Kincaid score was generated automatically in Microsoft Word. The Patient Education Material Assessment Test (PEMAT), developed by AHRQ [25, 28], and the Clear Communication Index (Index), developed by the CDC [24], are validated scales that assess understandability of written materials. Both tools are previously described [12]. Two graders who did not design the pamphlet evaluated the pamphlet with these health literacy standards.

#### Interviews

We recruited adults with SCD from the Johns Hopkins Sickle Cell Center for Adults’ outpatient panel and a list of patients from a previous study who agreed to be contacted



**Fig. 1** Methodology for collaborative development of patient education material

for future research. Inclusion criteria included 21–35 years old, English-speaking, and comfortable reading a two-page pamphlet. We designed a purposeful sampling technique [29] to target individuals with a range of education levels. We recruited one man and one woman who (a) completed high school or less, (b) had some college experience, and (c) completed college or more, and one additional man and woman with any level of education.

We recruited provider participants using a purposeful sample targeting one hematologist; one advanced practice provider from the Sickle Cell Center; two reproductive endocrinology-infertility fellows or faculty; and two genetic counselors in the obstetrics and gynecology department. A medical student emailed these divisions inviting participation from eligible faculty or staff.

Participants provided verbal consent. Two trained medical students conducted interviews virtually. Patient participants were interviewed by phone, and provider participants through a video conferencing platform. All participants received a PDF of the pamphlet prior to the interview and had unlimited time at the start of the interview to review the material. The interviewers asked open-ended questions from one of three semi-structured interview guides: one each for patients, hematologists, and genetic counselors and reproductive endocrinologists. Multidisciplinary consultants with experience in qualitative research refined the guides prior to their use (Supplemental material 2). The guides included questions about whether any aspects of the pamphlet were

confusing, features that improved or hindered understanding, emotional reactions, and recommendations for future use. After five interviews were completed, we added questions to address issues that emerged: how to discuss cost of IVF + PGT and the appropriateness of phrases including “spontaneous pregnancy,” “embryo,” and “mother/father.”

All patient participants were compensated with \$30 gift cards. The interview period lasted from June 2020 to March 2021. Interviews were recorded, deidentified, and transcribed by a secure transcription service [30].

### Interview analysis

For the health literacy scales, arithmetic means of the two graders’ scores for the pamphlet were reported with inter-rater percent agreement.

The five-member coding team analyzed interviews using grounded theory, a qualitative content analysis framework [31]. The code team, two of whom had previous qualitative research experience, was trained by reviewing and discussing qualitative methods described in published literature [31, 32]. No coding team member was a provider or patient stakeholder, though all team members were medical students at the same institution. All members of the code team read and coded the first two expert and patient interviews. The team developed a consensus preliminary codebook with code trees, definitions, and examples.

Two coders independently reviewed and coded each transcript using the preliminary codebook and proposed new codes as necessary. Coding dyads met together to discuss codes and reached consensus on each transcript. The full coding team met periodically to debate new codes and refine preliminary codes. We determined whether saturation of themes was reached with the first round of purposeful sampling by assessing whether any new higher-level codes were added when coding the last transcript. Coding dyads re-coded transcripts using the final codebook. The coding team met to finalize classification of codes into trees. From these trees, key themes were proposed and refined by research team members until consensus was achieved.

### Pamphlet revision

We revised the pamphlet to comply with the standards in the health literacy scales, as described below. We incorporated interviewee feedback except where opinions contradicted each other or where the suggestion was determined to be outside the pamphlet's scope. The final pamphlet was re-scored using the Flesch-Kincaid, PEMAT, and Index.

## Results

### Pamphlet design

The initial pamphlet was a double-sided, full-color introduction to reproductive options for people with SCD or SCT. The initial pamphlet addressed hemoglobin electrophoresis testing, family planning options, details of IVF + PGT, the multidisciplinary experts involved in reproductive care, and a list of steps to support patients' decision-making.

### Pamphlet evaluation

The Joint Commission recommends writing materials at a 5th grade reading level [18]. The Flesch-Kincaid score for the initial pamphlet was 7th grade. The AHRQ recommends PEMAT scores greater than 70% [28]. The initial pamphlet met a mean of 84% of PEMAT standards (82% agreement). The CDC recommends Index scores greater than 90% [24]. The initial pamphlet met a mean of 78% of Index standards (94% agreement). The initial pamphlet did not meet the following standards: it did not "almost always" use the active voice (PEMAT item 5), explain what is not known about the topic (Index item 11), or sufficiently address both risks and benefits (Index items 18 and 19). We addressed these shortcomings during final revisions, as detailed below.

Researchers contacted 22 eligible patients for interviews and 13 consented to participate. We excluded three men with a high school education due to missed interviews, and

one woman with a high school education disenrolled due to hospitalization. We mistakenly recruited and interviewed an additional woman with some college education after meeting the "some college" quota. Analysis of her interview was underway when the error was identified. We decided to include the data from her interview. Our analyses aimed to represent the breadth of patient perspectives, and themes were not selected based on the frequency with which the idea was expressed, so we were not concerned that adding an additional patient with some college education would bias the results. We completed all other purposeful sampling categories, so there were nine total patient participants. Twenty-four providers received division-wide emails inviting participation. Eight providers volunteered, and six were enrolled to meet sampling quotas. We filled each sampling category by enrolling participants in the order in which they volunteered.

The patients were 21–29 years old. Two patients were college graduates, two had a high school education, and five had completed some college coursework. Most had hemoglobin SS disease (56%), while others had SC (33%) and S $\beta$ <sup>+</sup> thalassemia (11%). Of the six clinicians, all were female; four were non-Hispanic White, one was Black, one was South Asian, and one was Hispanic White. They included two attending physicians, a reproductive endocrinologist and a hematologist; one fellow in reproductive endocrinology; one advanced practice provider from the Sickle Cell Center; and two genetic counselors. Interview length was 10 to 45 min.

### Interview analysis

We identified seven key themes about attitudes towards the pamphlet and its distribution. Table 1 provides themes with exemplar quotes.

*Theme 1. Clear, concise overview of a complicated topic:* Patient and providers thought the pamphlet was straight-forward and understandable; several described the pamphlet as "self-explanatory." Features that aided in understanding included a glossary of terms, graphics depicting the steps of the IVF + PGT process, and a bulleted summary.

*Theme 2. Useful to patients and providers:* Patients were asked if they would recommend this pamphlet to a friend or family member with SCD or SCT. All stated that they would recommend it ( $n = 9$ , 100%). Several named specific individuals for whom it would be useful. Many patients ( $n = 6$ , 67%) spontaneously stated that the pamphlet would be useful for their own future family planning. Providers imagined incorporating the pamphlet into their workflows before visits as an introduction to the topic, during visits to structure conversa-

**Table 1** Themes with exemplar interview excerpts show patient and provider acceptance of pamphlet

Theme	Patient interview excerpts	Provider interview excerpts
<b>Pamphlet strengths</b>		
1. Clear, concise overview of a complicated topic	“But to me, the pamphlet was very easy to read. Pretty easy to digest” — Patient, 28 M	“This is obviously a super complex topic, and I think it does a good job of kind of breaking it down and introducing a 10,000 foot overview of how IVF can help prevent people who are at risk for sickle cell disease passing it on to a child” — Reproductive Endocrinologist
2. Useful to patients and providers	“It was just perfect for me because this was something that me and my wife had talked about before, and we weren’t sure about the details of the process... And now I can ask more from my doctor and all that sort of stuff” — Patient, 26 M	“Any time that you have a patient handout that lists the steps of PGT is so helpful because it’s something that, in preconception counseling, you really need to walk through it with them one step at a time and make sure that you are giving them material to go home with and really ruminates on” — Genetic counselor
3. Appropriate for distribution online and in clinic	“I use social media; I feel like it’s a great outlet. More people can get educated and then they can hook up with a doctor to talk about this process together” — Patient, 28 M	“If I had a patient who was thinking about having a child and I’m counseling them on it, I would say, ‘Here take this home. Read about it. And then come back to me’” — Hematologist
4. Universally acceptable to participants and hopeful for patients	“I felt a little bit lighter knowing that I still have options if I wanted to have a child. I’m 26 now, so it’s something that I do think about. So I feel like I know a little bit more just with this pamphlet alone” — Patient, 26F “Honestly, I was excited about it, because I had really come to the conclusion that I had to adopt...that adoption is my only choice unless they find a cure... And I keep thinking, ‘This sucks.’...But the pamphlet gives me kind of hope that it doesn’t have to go that route if I don’t want it to...So yeah, it helped quite a bit” — Patient, 24F	Interviewer: “Is there anything that would make you less likely to share this with patients?” Participant: “No. It is good information. This is going to make them more knowledgeable. If they know about this, it’s going to give them more insight” — Advanced practice provider, Sickle Cell Center
<b>Suggestions for improvement</b>		
5. Lacking information about uncertainties and risks, including potential cost	“I know that it says you can do a treatment where... they could try to pick the embryo that doesn’t carry the genes during the IVF treatment. But is that for sure? Is that 100%?” — Patient, 22F “And there’s no explanation of how much it would cost...I think that’s my biggest thing” — Patient 26F	“But plenty of people, IVF and PGT is really not an option for them. We can tell them all we want, ‘Oh you have options. You have options.’ And they really don’t if it’s going to cost them 20 K out of pocket” — Genetic counselor
6. Disagreement about gendered language and inclusivity	“I understand that you feel some type of way about mother/father, but in reality, the father has sperm; the mother has eggs and ovaries, end of story. A guy can’t have ovaries and eggs. It’s just a medical fact...I feel like trying to use female or male, it kind of makes it too generic” — Patient, 24F	“This pamphlet is very, very not sensitive to issues of gender identity, and I would not want to give this pamphlet to a trans patient. There are lots and lots of instances throughout the pamphlet where it talks about the mother and the father” — Genetic counselor “As someone who is not particularly religious, I think my reaction was like, well I don’t necessarily need a spiritual advisor. ...It just seemed a little bit narrow” — Reproductive Endocrinologist
7. Not sufficiently explicit that IVF + PGT can prevent SCD	“I guess a question I would have is if you could do PGT without doing in vitro or if you could do one without the other, if it’s a process that you have to do together” — Patient 26F	“Where it says, ‘in vitro fertilization with preimplantation genetic testing is one option to have a child,’ I think...it’s not clear that the reason why you’re doing this is to decrease your chance of having a child with sickle cell disease. I know it says it there; it’s just not emphasized enough for it to be clear that this is what this is for” — Genetic counselor

Themes were articulated and defined by research team members based on collaborative code book. Representative quotes were selected with the goal of representing the key points encompassed by each theme, where appropriate, patient, and provider perspectives were included



tion, or after visits as a summary. The genetic counselors identified the stepwise description of IVF + PGT in the pamphlet as filling an unmet need: “I appreciate that [IVF + PGT] is the part that is discussed in detail because when a patient comes in to a genetic counseling visit, patients often have questions about the IVF process, but I’m not the IVF expert.”

*Theme 3. Appropriate for distribution online and in clinic:* Patients recommended disseminating the pamphlet through a website, social media, online SCD support groups, or at local clinics. Providers envisioned distributing the pamphlet during clinic visits. Other suggestions included emailing the pamphlet to a clinic’s patient list and circulating the material through SCD organizations.

*Theme 4. Universally acceptable to participants and hopeful for patients:* Provider and patient participants did not express concerns about pamphlet topic or content or raise concerns about reproductive coercion or eugenics. Patients reported a sense of “empowerment” from learning about their reproductive options. One patient appreciated new knowledge about reducing the risk of SCD in children saying, “I don’t know anybody who would actively want their child to have sickle cell disease.” When asked about their emotional reactions after reading the pamphlet, patients reflected on the possibility of biological parenthood with reduced risk of passing SCD to children and expressed optimism and hope.

*Theme 5. Lacking information about uncertainties and risks, including potential cost:* Participants suggested inclusion of more information about the benefits, uncertainties, and risks of IVF + PGT. All participants requested more information about the cost of IVF + PGT. Patients and providers identified that procedural and financial risks and benefits need to be individualized. However, they recommended briefly mentioning common risks to guide conversations with providers. Patients wanted information about the uncertainties of IVF + PGT, such as diagnostic accuracy and chances of successful pregnancy. Others wanted more information about the experience of the IVF + PGT process, especially related to ovarian stimulation and oocyte harvest.

*Theme 6. Disagreement about gendered language and inclusivity:* Providers criticized a lack of inclusive language related to gender identity, family structure, and religious affiliation. The concern centered on the repeated use of “mother” and “father,” which excluded transgender people and those with nontraditional family structures. The revised patient interview guide included a question about the use of gendered language. Among the seven patients interviewed after the revision, two recommended using less gendered terms, while five recommended keeping “mother” and “father.” Some of these patients

( $n = 3$ ) believed gender neutral language like “male” and “female” dehumanized the pamphlet.

Finally, all participants supported the inclusion of a spiritual advisor in the section outlining members of the care team. However, one patient and one provider worried that referencing a spiritual advisor as a resource when considering issues of embryo selection and disposal might be exclusionary for non-religious readers.

*Theme 7. Not sufficiently explicit that IVF + PGT can prevent SCD:* Providers worried that the purpose of IVF + PGT was not explained explicitly enough to ensure patient understanding. Patients suggested defining IVF + PGT earlier in the pamphlet. Another patient revealed, through their follow-up questioning, a lack of understanding about the function of PGT in the context of IVF, suggesting the pamphlet insufficiently explained this topic.

## Revision and re-scoring

We revised the pamphlet based on the health literacy scales and stakeholders’ interviews. We explicitly stated the purpose of IVF + PGT in the first half of the revised pamphlet and outlined the procedure’s risks and benefits, including possible high costs. We included captions with the graphics illustrating the steps of IVF + PGT. We noted the accuracy rate of PGT testing and the possibility that a patient might not become pregnant. Although opinions were divided on the issue of inclusive language, we edited the pamphlet to be more broadly inclusive of gender identity, family structure, and religiosity. Language was simplified to minimize reading level. After we completed all steps, over 40 stakeholders (Fig. 2) had contributed to the development of the revised pamphlet (Fig. 3), which has a Flesch-Kincaid reading grade level of 5.7 and met 97% of PEMAT (percent agreement = 94%) and 91% of Index (percent agreement = 82%) standards.

## Discussion

A pamphlet about reproductive options for people with SCD or SCT, including information about IVF + PGT as a method to reduce the risk of SCD in offspring, was unanimously acceptable to a sample of adults with SCD and clinicians. Participants identified the tool as useful, clear, concise, and understandable. The revised pamphlet meets national guidelines for plain language; this complex topic can be introduced at a fifth-grade reading level and meet both AHRQ and CDC understandability standards.


We hypothesized that some patients and providers would express concern related to ethical issues like marital control, selective abortion, or eugenics [14, 33, 34]. However, no patient or provider referenced these issues or found the pamphlet inappropriate or offensive. The results of this study add to the growing body of literature confirming that people with SCD find information about reproductive options including IVF + PGT acceptable [4–6]. This non-directive resource created with patient input can provide clinicians with a template for shared decision-making and serve as an introduction to patients, a discussion aid, or a visit summary to improve patient understanding.

We previously identified that existing written patient education materials about IVF + PGT exceed the reading level of average Americans [12]. Here, we demonstrate that creating educational materials about reproductive options including IVF + PGT that are accessible to average Americans is possible. Wide availability of understandable materials may expand patient awareness of reproductive options and facilitate conversations between patients and their care teams

[3–6]. By meeting health literacy standards, this pamphlet includes those with low educational attainment, a group with disproportionately low utilization of ART [35], in the conversation about IVF + PGT. We are aware of one other patient education tool describing reproductive options for people with SCD or SCT [6]. This material targets parents of children with SCD and is written at a higher reading level. Both materials contribute to the closing of this resource gap.

Patient and provider participants recommended including information about the cost of and the chance of becoming pregnant through IVF + PGT, though both of these figures are variable and uncertain. In the USA, direct costs to patients of ART vary significantly by insurance [36]. There is sparse data regarding success rates of IVF + PGT in SCD [37], and no study analyzes success rates in a US sample. Participants were clear that this information is essential to set accurate expectations related to IVF + PGT, so we added text to briefly introduce financial and other harms while directing patients to experts for more individualized risk assessments.

**Fig. 2** More than 40 diverse SCD stakeholders involved in pamphlet development




**Fig. 3** Family planning options for people with SCD or SCT


## Family Planning Options for Couples with Sickle Cell Trait or Sickle Cell Disease (SCD)

If you have SCD or trait, you have choices for how to start your family


The first step in family planning is learning if you and your partner have gene changes that lead to a chance of having a child with sickle cell disease (SCD). You can get a blood test to check (hemoglobin electrophoresis). Ask your doctor to order this test and to explain your results. If the test shows there is a chance your future child could have SCD, and you want to learn more, there are many people who can help you think about how to have a child.




**Reproductive Endocrinologist (Fertility Doctor)**  
Knows the steps, risks, and cost of medical options



**Hematologist (Blood Doctor)**  
Knows what to expect with SCD and your child



**Genetic Counselor**  
Explains your child's risk for having SCD and helps you think about your options



**Spiritual Advisor**  
May help guide your family planning choices to fit your values

Who can help?

**Some of your choices are: (see glossary for definitions)**

- Pregnancy from having sex
- Adoption
- Donor egg/sperm
- Surrogacy
- In vitro fertilization and Preimplantation genetic testing (IVF+PGT)

**In vitro fertilization + Preimplantation genetic testing:** is one option to have a child for people who want to lower the chance their child will have SCD. Some benefits and risks are:

<p><b>Benefits:</b></p> <ul style="list-style-type: none"> <li>• Child has genes from you and your partner</li> <li>• Can lower chance your child will have SCD</li> </ul>	<p><b>Risks:</b></p> <ul style="list-style-type: none"> <li>• Pain and discomfort</li> <li>• Sometimes very high cost (depends on insurance)</li> <li>• Can be very stressful</li> </ul>
--	--

The back of this pamphlet has details about IVF+PGT .

**summary:**

1. Ask your doctor to order a hemoglobin electrophoresis blood test for you and for your partner to check for gene changes in your blood cells.
2. Adoption, donor egg/sperm, and IVF + PGT lower the chance that your child will have SCD. If that is one of your goals, ask your doctor to send you to a genetic counselor or fertility doctor (reproductive endocrinologist), who can help you learn more.
3. IVF + PGT lets you combine egg and sperm from you and your partner in a lab to make embryos. Lab workers can test the embryos for SCD before putting one in the female's womb.

**Next step:** have a visit with your primary doctor or blood doctor (hematologist) who can refer you to other team members

Our participants identified two avenues for pamphlet distribution: (1) directly to patients through social media, websites, or SCD organizations and (2) through providers alongside clinic visits. Direct distribution to patients could expand awareness of reproductive options in SCD, while distribution through providers creates space for follow-up questions and personalization. We will partner with the Sickle Cell Reproductive Health Education Directive, a collaborative patient-provider organization [38], to disseminate the pamphlet via both suggested pathways.

Reliance on self-report to affirm pamphlet comprehension has methodological limitations. Participants may be uncomfortable revealing their lack of understanding. This discomfort may especially be attributable to power dynamics


between patient and interviewer [39] or discrepancy between education level and reading ability. Both concerns might lead patient participants to overstate their understanding of the material. Interviewers attempted to overcome this barrier by using prompts that normalized and invited this disclosure. In this sample, most patient participants completed some college coursework; however, education level tends to overestimate reading ability [40] and adults with SCD often have insidious neurocognitive injury [41, 42]. Some participants' reading ability may have been meaningfully beneath their education level. Together, these possibilities highlight that education material about reproductive options related to SCD, even one written at a fifth grade reading level, should be used in coordination with appropriate and comprehensive




Fig. 3 (continued)

## In Vitro Fertilization (IVF) and Preimplantation Genetic Testing (PGT): how does the process work?


- 1. Ovarian Stimulation:** The doctor gives medicine to release the female's eggs  
The female gives herself shots one or more times daily for about one to two weeks to help her grow many eggs at once. When the eggs are big enough, she will give herself a shot to cause them all to mature at the same time.




shots are taken to grow eggs
- 2. Retrieval:** The doctor removes the eggs from the ovaries  
The doctor uses a long, thin needle to remove eggs through the vagina using an ultrasound to see. The female is asleep, and she may feel some cramping after.




doctor takes eggs from ovaries (yellow)
- 3. Fertilization:** The eggs and sperm are combined in the lab.  
On the day the eggs are removed, the male gives a sperm sample. The eggs and sperm are combined to form embryos with genes from both the male and female.




eggs and sperm make embryos
- 4. Culturing:** The embryos grow in the laboratory  
The embryos grow for about five days. They are scored based on how healthy they are. Parents get information about the embryos as they grow.




embryos grow in a lab
- 5. Preimplantation Genetic Testing:** Cells are tested for SCD  
A few cells are taken from a part of the embryos that will not form the baby and are sent to a lab, where they are tested for genes that cause SCD. Results come in 1-2 weeks. The test is wrong less than 1% of the time (less than 1 time in 100 tests).



lab tests genes from embryos
- 6. Embryo Selection:** Parents and doctors choose which embryo to use  
Parents get a report about the health of the embryos and which ones have SCD. The parents and the doctor choose an embryo to put in the female's womb. They may pick one without SCD if they want to lower the chance their child will have SCD. There is a chance that all the embryos will have the genes that cause SCD. Some people have concerns about how to pick an embryo or what to do with unused ones. You can talk to people you trust, like family, friends, and spiritual advisors.



embryo is chosen based on health and genes
- 7. Transfer:** An embryo is placed in the female's womb  
This is a procedure that uses ultrasound. The female is awake and often feels no pain. If the embryo attaches to the womb, the female becomes pregnant. You can try again with extra embryos, and you can also freeze them to use later.



embryo can grow into a baby in the womb

**glossary:**

**Donor egg/sperm:** using egg or sperm from a person without the gene that causes SCD. Prevents the child from having SCD. The child will be biologically related to one parent.

**Embryo:** an early stage of fetal growth where the baby is a handful of cells with genes from the male and female parent.

**Hemoglobin electrophoresis:** a blood test that tells you about the building blocks that make up your blood cells, called the hemoglobin. The test shows gene changes, like the sickle cell gene and others, that put your child at risk for SCD.

**In vitro fertilization:** a process that helps a female get pregnant. The process where a female gets shots to grow eggs and embryos made in the lab are placed inside the womb. You cannot have PGT without IVF.

**Preimplantation genetic testing:** can add to IVF. Checks for gene changes in an embryo before putting it in the womb.

**Sickle cell disease:** a genetic disease of the blood cells that can cause pain, strokes, lung infections, and organ damage.

**Surrogacy:** a family planning choice where a male and female who want to be parents make an embryo in the lab, and it is put in a different female to carry the pregnancy.

clinical care and counseling for individuals with SCD and their families [8].

In addition, participants did not review the revised pamphlet, but our partnership with the Sickle Cell Reproductive Health Education Directive [38] will allow stakeholder input prior to dissemination. Our patient participants were all people with SCD less than 30 years old. While all people with SCD or SCT of reproductive age are the targeted audience for this pamphlet, young people are most likely to be making initial reproductive decisions, and people with SCD are at the highest risk for passing SCD to children and might experience particularly poignant emotions in response to conversations about reproductive options. Future studies should include patients from other geographic regions,

parents of children with SCD, people with SCT, and primary care providers.

This mixed-method study engaged patient and provider stakeholders to rigorously develop and evaluate a pamphlet about reproductive options for individuals with SCD or SCT written at the fifth-grade reading level. Despite the potentially sensitive nature of the topic, the material was acceptable and useful to participants. This pamphlet may serve as a resource to share information and enable proactive, informed reproductive decisions.

**Abbreviations** AHRQ: Agency for Healthcare Research and Quality; ART: Assisted reproductive technology; CDC: Centers for Disease Control and Prevention; Index: CDC Clear Communication Index;

IVF: In vitro fertilization; PEMAT: Patient Education Material Assessment Tool; PGT: Preimplantation genetic testing; SCD: Sickle cell disease

**Supplementary Information** The online version contains supplementary material available at <https://doi.org/10.1007/s10815-021-02358-z>.

**Acknowledgements** The authors thank SiNERGe, the Northeast Regional Sickle Cell Collaborative, for feedback and support throughout the project; Sheree Gatewood, Cathleen Lawson, and Joann Bodurtha for expert input on the material's content; and Gail Geller and Joseph Carrese for mentorship in study design.

**Author contribution** MLE, SL, MSC, and LHP designed the research study and provided input for pamphlet content. MLE and IVL developed and revised the pamphlet. RJS, SMS, JAR, and JAS scored the pamphlet using health literacy scales. MLE and RJS conducted participant interviews. MLE, JAR, JAS, SMS, and RJS completed qualitative analysis of interviews. MLE, JWM, ERM, and LHP guided final data analysis and presentation. MLE and LHP wrote the manuscript, with significant editorial revision by JWM and ERM. All authors provided final input into the manuscript.

**Funding** MLE is supported by the American Society of Hematology Physician-Scientist Career Development Award. JAS is supported by the Ruth L. Kirschstein NRSA-F30 Research Fellowship from the National Cancer Institute. LHP is supported by a K23 from the National Heart, Lung, and Blood Institute.

**Data availability** Not applicable.

**Code availability** Not applicable.

## Declarations

**Ethics approval** The study was approved by the Johns Hopkins School of Medicine Institutional Review Board.

**Consent to participate** Patients provided verbal consent to participate using an IRB-approved consent script.

**Consent for publication** Not applicable.

**Conflict of interest** MLE, IVL, JAR, JAS, SMS, JWM, MSC, and LHP have nothing to disclose. RJS discloses publication of an opinion article on privately owned fertility clinics in NBC News. ERM reports personal fees from CVS Caremark, Novartis, Novo Nordisk, and Forma Therapeutics and grants and personal fees from Global Blood Therapeutics, all outside of the submitted work. SL reports personal fees from Bluebird Bio and Novo Nordisk and other financial disclosures from Global Blood Therapeutics, Imara, Shire, Novartis, Pfizer, and Teva, all of which are outside the submitted work.

## References

- Pecker LH, Naik RP. The current state of sickle cell trait: implications for reproductive and genetic counseling. *Blood*. 2018;132:2331–8.
- Dreesen J, Destouni A, Kourlaba G, et al. Evaluation of PCR-based preimplantation genetic diagnosis applied to monogenic diseases: a collaborative ESHRE PGD consortium study. *Eur J Hum Genet*. 2014;22:1012. <https://doi.org/10.1038/EJHG.2013.277>.
- Gallo AM, Wilkie D, Suarez M, et al. Reproductive decisions in people with sickle cell disease or sickle cell trait. *West J Nurs Res*. 2010;32:1073–90. <https://doi.org/10.1177/0193945910371482>.
- Darbari I, O'Brien JE, Hardy SJ, et al. Views of parents of children with sickle cell disease on pre-implantation genetic diagnosis. *Pediatr Blood Cancer*. 2018;65:e27102. <https://doi.org/10.1002/pbc.27102>.
- Schultz CL, Tchume-Johnson T, Jackson T, et al. Reproductive intentions in mothers of young children with sickle cell disease. *Pediatr Blood Cancer*. 2020;67(5):e28227. <https://doi.org/10.1002/pbc.28227>.
- Attia M, Kripalani S, Darbari I, Nickel RS. Parents of children with sickle cell disease are interested in preimplantation genetic testing. *J Pediatr*. 2020;223:178–182.e2. <https://doi.org/10.1016/j.jpeds.2020.04.027>.
- Oyewo A, Salubi-Udu J, Khalaf Y, et al. Preimplantation genetic diagnosis for the prevention of sickle cell disease: current trends and barriers to uptake in a London teaching hospital. *Hum Fertil*. 2009;12:153–9. <https://doi.org/10.1080/14647270903037751>.
- National Academies of Sciences, Engineering and Medicine. Addressing sickle cell disease: a strategic plan and blueprint for action. Washington, D.C; 2020.
- Bean CJ, Hooper WC, Ellingsen D, et al. Discordance between self-report and genetic confirmation of sickle cell disease status in African-American adults. *Public Health Genomics*. 2014;17:169–72. <https://doi.org/10.1159/000360260>.
- Pecker LH, Sharma D, Nero A, et al (2021) Knowledge gaps in reproductive and sexual health in girls and women with sickle cell disease. *Br J Haematol* 194:970–979. <https://doi.org/10.1111/BJH.17658>
- Klitzman R, Chung W, Marder K, et al. Views of internists towards uses of PGD. *Reprod Biomed Online*. 2013;26:142–7. <https://doi.org/10.1016/j.rbmo.2012.11.006>.
- Early ML, Kumar P, Marcell AV, et al. Literacy assessment of preimplantation genetic patient education materials exceed national reading levels. *J Assist Reprod Genet*. 2020;37(8):1913–22. <https://doi.org/10.1007/s10815-020-01837-z>.
- Strauss V (2016) Hiding in plain sight: The adult literacy crisis. In: *The Washington Post* (Washington D.C.). Accessed online 1 Oct 2021
- Silliman J, Gerber Fried M, Ross L, Gutierrez ER. *Undivided rights: women of color organize for reproductive justice*. Cambridge: South End Press; 2004.
- Fort AT, Morrison JC, Berreras L, et al. Counseling the patient with sickle cell disease about reproduction: pregnancy outcome does not justify the maternal risk! *Am J Obstet Gynecol*. 1971;111:324–7. [https://doi.org/10.1016/0002-9378\(71\)90772-1](https://doi.org/10.1016/0002-9378(71)90772-1).
- Strasser BJ, Fantini B. Molecular diseases and diseased molecules: ontological and epistemological dimensions. *Philos Life Sci*. 1998;20:189–214.
- Nielsen-Bohlman L, Panzer AM, Kindig DA. *Health literacy: a prescription to end confusion*. Washington, D.C: National Academies Press; 2004.
- “What did the doctor say? Improving health literacy to protect patient safety.” The Joint Commission (2007) [www.jointcommission.org](http://www.jointcommission.org)
- O'Brien BC, Harris IB, Beckman TJ, et al. Standards for reporting qualitative research: a synthesis of recommendations. *Acad*

- Med. 2014;89:1245–51. <https://doi.org/10.1097/ACM.0000000000000388>.
20. Speer J (2019) How IVF and genetic testing can help prevent sickle cell anemia. in: reproductive medicine associates of connecticut. <https://www.rmact.com/fertility-blog/how-ivf-and-genetic-testing-can-prevent-sickle-cell-anemia>. Accessed 15 Aug 2021
  21. Malcolm E (2020) Reproductive options if you are a pompe disease carrier. In: Pompe Disease News. <https://pompedisease.com/news/2020/06/09/reproductive-options-pompe-disease-carriers-ivf-minimize-risk/>. Accessed 15 Aug 2021
  22. Reproductive options considering hemophilia. In: Indiana Hemophilia & Thrombosis Center. <https://www.ihtc.org/hemophilia-reproductive-options>. Accessed 15 Aug 2020
  23. Perkins M, Obrecht C, Adams C. Canva (2012) [www.canva.com](http://www.canva.com)
  24. Baur C, Prue C. The CDC clear communication index is a new evidence-based tool to prepare and review health information. *Health Promot Pract*. 2014;15:629–37. <https://doi.org/10.1177/1524839914538969>.
  25. Shoemaker SJ, Wolf MS, Brach C (2014) The patient education materials assessment tool (PEMAT) and user's guide. Agency for Healthcare Research and Quality. [www.ahrq.gov](http://www.ahrq.gov)
  26. McGee J, M&E Consulting (2010) Toolkit for making written material clear and effective. Centers for Medicare and Medicaid Services. [www.cms.gov](http://www.cms.gov)
  27. Kincaid J, Fishburne RJr, Rogers R, Chissom B. Research branch report 8–75: derivation of new readability formulas (automated readability index, fog count, and flesch reading ease formula) for Navy enlisted personnel. Memphis; 1975.
  28. Shoemaker SJ, Wolf MS, Brach C. Development of the patient education materials assessment tool (PEMAT): a new measure of understandability and actionability for print and audiovisual patient information HHS Public Access. *Patient Educ Couns*. 2014;96:395–403. <https://doi.org/10.1016/j.pec.2014.05.027>.
  29. Palinkas LA, Horwitz SM, Green CA, et al. Purposeful sampling for qualitative data collection and analysis in mixed method implementation research. *Adm Policy Ment Health*. 2015;42:533. <https://doi.org/10.1007/S10488-013-0528-Y>.
  30. TranscribeMe, Inc. San Francisco, CA. (2011) [www.transcribeme.com](http://www.transcribeme.com)
  31. Graneheim UH, Lundman B. Qualitative content analysis in nursing research: concepts, procedures and measures to achieve trustworthiness. *Nurse Educ Today*. 2004;24:105–12. <https://doi.org/10.1016/j.nedt.2003.10.001>.
  32. Cascio MA, Lee E, Vaudrin N, Freedman DA. A team-based approach to open coding: considerations for creating intercoder consensus. *Field Methods*. 2019;31:116–30. <https://doi.org/10.1177/1525822X19838237>.
  33. Culliton BJ. Sickle cell anemia: national program raises problems as well as hopes. *Science*. 1972;178:283–6. <https://doi.org/10.1126/science.178.4058.283>.
  34. Wailoo K. The troubled dream of genetic medicine: ethnicity and innovation in Tay-Sachs, cystic fibrosis, and sickle cell disease. 1st ed. Baltimore: Johns Hopkins University Press; 2006.
  35. Stephen EH, Chandra A, King RB. The supply of and demand for assisted reproductive technologies in the United States: clinic and population based data, 1995–2010. *Fertil Steril*. 2016;105:451. <https://doi.org/10.1016/J.FERTNSTERT.2015.10.007>.
  36. Kilbride MK. In vitro fertilisation with preimplantation genetic testing: the need for expanded insurance coverage. *J Med Ethics*. 2020;0:1–5. <https://doi.org/10.1136/MEDET-HICS-2019-105879>
  37. Vali S, Mukhtar S, Nandi A, et al. Cumulative outcome of pre-implantation genetic diagnosis for sickle cell disease: a 5-year review. *Br J Haematol*. 2020;191:875–9. <https://doi.org/10.1111/bjh.16930>.
  38. The Sickle Cell Reproductive Health Education Directive. <https://sicklecellred.org/>. Accessed 25 Aug 2021
  39. Graham S, Brookey J. Do patients understand? *Perm J*. 2008;12:67. <https://doi.org/10.7812/TPP/07-144>.
  40. Ryan E, Baird R, Mindt MR, et al. Neuropsychological impairment in racial/ethnic minorities with HIV infection and low literacy levels: effects of education and reading level in participant characterization. *J Int Neuropsychol Soc*. 2005;11:889. <https://doi.org/10.1017/S1355617705051040>.
  41. Vichinsky EP, Neumayr LD, Gold JJ, et al. Neuropsychological dysfunction and neuroimaging abnormalities in neurologically intact adults with sickle cell anemia. *JAMA*. 2010;303:1823–31. <https://doi.org/10.1001/jama.2010.562>.
  42. Martin S, Roderick MC, Abel C, et al. Neurocognitive functioning in symptomatic adults with sickle cell disease: a description and comparison with unaffected siblings. *Neuropsychol Rehabil*. 2019;30:1666–81. <https://doi.org/10.1080/09602011.2019.1598876>.

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.